ABSTRACT
The human papillomavirus (HPV) is the most common sexually transmitted virus.HPV vaccine to prevent HPV infection has become a primary preventive measure for cervical cancer and has been applied in many countries and regions around the world.The application of therapeutic HPV vaccine has become a hot point in the research of HPV.
ABSTRACT
Objective:To explore the biological function of miR-132 in ovarian cancer and the target. Methods: 22 cases ovarian cancer tissue and non-tumor tissue adjacent were collected,the expression of miR-132 in tumor tissue and non-tumor tissue, normal ovarian epithelial cells and ovarian cancer cell were detected by RT-PCR. The normal ovarian epithelial cells which the expression of miR-132 maximum or minimum were chosen, and they were divided into two groups, respectively with transfection of negative control plasmid ( NC) and miR-132 mimic plasmid. The expression of miR-132 after transfection was detected by RT-PCR,the cell proliferation and cell apoptosis were detected by CCK-8 method and flow cytometry instrument respectively,the expression of Ezrin protein was detected by Western blot. Results:The expression of miR-132 in tumor tissue was significantly lower than the tumor tissue adjacent,the expression of miR-132 in ovarian cancer cell lines was significantly lower than normal ovarian epithelial cells, the differences were statistically significant (P<0. 05). The SKOV3 cell lines was chosed for gene transfection,compared with NC group, transfection with miR-132 mimic plasmid could significantly reduce cell proliferation, increase cell apoptosis, the difference had statistical significance ( P<0. 05 ) . Western blot results showed that up-regulation miR-132 significantly increased the Ezrin protein expression in ovarian cancer SKOV3 cells ( P<0. 05 ) . Conclusion: In ovarian cancer, miR-132;inhibits proliferation and induces apoptosis of ovarian cancer via Ezrin,it may be a tumor suppressor gene.
ABSTRACT
Background and purpose:The aim of this study was to analyze the prognostic factors in uterine adenocarcinoma and adenosquamous carcinoma treated with a combination of neoadjuvant chemoradiotherapy and surgery.Methods:Clinicopathologic data from 50 patients with stageⅠB2-ⅡA2 uterine cervical cancer were collected from the First Afifliated Hospital of Bengbu Medical College between Apr. 2005 and Oct. 2011. All patients underwent neoajuvant chemoradiotherapy, followed by radical hysterectomy and pelvic lymph node dissection. Before surgery, an intravenous chemotherapy was given. A particular vaginal brachytherapy was given to those with tumor diameter≥6 cm. The survival and recurrence in patients were analyzed retrospectively to investigate the prognostic factors. Results:In 50 patients withⅠB2-ⅡA2 uterine adenocarcinoma and adenosquamous carcinoma, 15 died during the follow-up period. The 2-year and 5-year progression-free survival rates were 80.12% and 72.24%, respectively, and median progression-free survival was 68 months. The 2-year and 5-year overall survival rates were 95.38% and 73.56%, respectively, and median overall survival was 80 months. Univariate analysis revealed that pelvic lymph node metastasis, cervical stromal invasion, parametrial infiltration, tumor diameter reduction 0.05). Multivariate Cox proportional analysis revealed that pelvic lymph node metastasis and tumor diameter reduction after radiation and chemotherapy were the independent prognostic factors in patients with cervical cancer. Conclusion:The combination of neoadjuvant chemotherapy and surgery improves the resectable rate of patients withⅠB2-ⅡA2 uterine adenocarcinoma and adenosquamous carcinoma. Pelvic lymph node metastasis and tumor diameter reduction after radiation and chemotherapy are the independent prognostic factors in patients with cervical cancer.
ABSTRACT
Purpose:To investigate the rational choice of adjuvant treatment and its clinical value for stage Ⅰb, Ⅱa cervical cancinoma after radical hysterectomy and pelvic lymphadenectomy.Methods:126 patients with stage Ⅰb and Ⅱa cervical cancer received adjuvant radiotherapy and/or chemotherapy after radical hysterectomy and pelvic lymphadenectomy .Of these patients, 64 received radiotherapy only, 26 chemotherapy only, 36 had both. The prognostic factors and treatment results were analyzed.Results:The overall 5-year survival rate for the 126 patients was 73%(92/126). For the radiotherapy only, chemotherapy only, and the radio-chemotherapy groups, the 5-year survival rates were 76.6%(49/64), 69.2%(18/26), and 69.4%(25/36) respectively. The clinical stages and the number of pelvic lymphnodes metastases were the most important prognostic factors. Conclusions:The value of adjuvant treatment for early stage cervical cancer after radical surgery was limited, but for patients who had more than two high risk factors, adjuvant treatment should be given, and at the same time, we should emphasis the importance of thoroughness of radical hysterectomy and pelvic lymphadenectomy.